Xenon Pharmaceuticals Valuation
Is XENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XENE?
Other financial metrics that can be useful for relative valuation.
|What is XENE's n/a Ratio?|
Price to Book Ratio vs Peers
How does XENE's PB Ratio compare to its peers?
|XENE PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
SAGE Sage Therapeutics
TWST Twist Bioscience
XENE Xenon Pharmaceuticals
Price-To-Book vs Peers: XENE is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (16.1x).
Price to Earnings Ratio vs Industry
How does XENE's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: XENE is expensive based on its Price-To-Book Ratio (2.8x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is XENE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate XENE's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of XENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XENE ($35.53) is trading below our estimate of fair value ($54.88)
Significantly Below Fair Value: XENE is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.